Combination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejection

Simple item page
dc.citation.firstpage20679en_US
dc.citation.issueNumber31en_US
dc.citation.journalTitleACS Nanoen_US
dc.citation.lastpage20693en_US
dc.citation.volumeNumber18en_US
dc.contributor.authorMeng, Tuoen_US
dc.contributor.authorZheng, Jinhuaen_US
dc.contributor.authorShin, Crystal S.en_US
dc.contributor.authorGao, Nanen_US
dc.contributor.authorBande, Divyaen_US
dc.contributor.authorSudarjat, Hadien_US
dc.contributor.authorChow, Woonen_US
dc.contributor.authorHalquist, Matthew Seanen_US
dc.contributor.authorYu, Fu-Shinen_US
dc.contributor.authorAcharya, Ghanashyamen_US
dc.contributor.authorXu, Qingguoen_US
dc.date.accessioned2024-08-09T16:25:25Zen_US
dc.date.available2024-08-09T16:25:25Zen_US
dc.date.issued2024en_US
dc.description.abstractHigh-risk (HR) corneal transplantation presents a formidable challenge, with over 50% of grafts experiencing rejection despite intensive postoperative care involving frequent topical eyedrop administration up to every 2 h, gradually tapering over 6–12 months, and ongoing maintenance dosing. While clinical evidence underscores the potential benefits of inhibiting postoperative angiogenesis, effective antiangiogenesis therapy remains elusive in this context. Here, we engineered controlled-release nanomedicine formulations comprising immunosuppressants (nanoparticles) and antiangiogenesis drugs (nanowafer) and demonstrated that these formulations can prevent HR corneal transplantation rejection for at least 6 months in a clinically relevant rat model. Unlike untreated corneal grafts, which universally faced rejection within 2 weeks postsurgery, a single subconjunctival injection of the long-acting immunosuppressant nanoparticle alone effectively averted graft rejection for 6 months, achieving a graft survival rate of ∼70%. Notably, the combination of an immunosuppressant nanoparticle and an anti-VEGF nanowafer yielded significantly better efficacy with a graft survival rate of >85%. The significantly enhanced efficacy demonstrated that a combination nanomedicine strategy incorporating immunosuppressants and antiangiogenesis drugs can greatly enhance the ocular drug delivery and benefit the outcome of HR corneal transplantation with increased survival rate, ensuring patient compliance and mitigating dosing frequency and toxicity concerns.en_US
dc.identifier.citationMeng, T., Zheng, J., Shin, C. S., Gao, N., Bande, D., Sudarjat, H., Chow, W., Halquist, M. S., Yu, F.-S., Acharya, G., & Xu, Q. (2024). Combination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejection. ACS Nano, 18(31), 20679–20693. https://doi.org/10.1021/acsnano.4c06595en_US
dc.identifier.digitalmeng-et-al-2024en_US
dc.identifier.doihttps://doi.org/10.1021/acsnano.4c06595en_US
dc.identifier.urihttps://hdl.handle.net/1911/117637en_US
dc.language.isoengen_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsExcept where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license.  Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleCombination Nanomedicine Strategy for Preventing High-Risk Corneal Transplantation Rejectionen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
meng-et-al-2024.pdf
Size:
14.45 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Materials Science and NanoEngineering Publications